Conference Coverage

CAR T before transplant yields durable remission in B-cell malignancies


 

REPORTING FROM THE 2018 BMT TANDEM MEETINGS

– Chimeric antigen receptor (CAR) T-cell therapy may be an effective bridge to hematopoietic cell transplant (HCT) for high-risk B-cell malignancies, according to a systematic analysis of patient data from the National Cancer Institute.

Additionally, patients who have received CAR T-cell therapy are likely to enter HCT with a minimal residual disease (MRD)–negative complete response, which raises the possibility of a significantly less intense conditioning regimen that could omit total body irradiation (TBI), Haneen Shalabi, DO, said at the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation.

“Patients who underwent HCT post–CAR T therapy did not have increased transplant-related morbidity or mortality,” said Dr. Shalabi, a pediatric oncologist in the hematologic diseases division of the National Cancer Institute’s pediatric oncology branch.

The combined approach also overcomes the frequent relapses seen after CAR T-cell therapy in this population. Of the 45 patients who received CAR T-cell therapy and achieved MRD-negative complete response as measured by flow cytometry, 20 did not go on to receive HCT. Of the 20 who didn’t receive HCT, 16 (80%) relapsed; 19 of the 20 (95%) had received prior HCT, said Dr. Shalabi.

Pages

Recommended Reading

Autologous stem-cell transplantation for scleroderma beats cyclophosphamide in long term
MDedge Hematology and Oncology
A mismatched haplotype may improve outcomes in second BMT
MDedge Hematology and Oncology
Checkpoint inhibitors look safe in rheumatology patients
MDedge Hematology and Oncology
Tisagenlecleucel looks effective in phase 2 study of young ALL patients
MDedge Hematology and Oncology
HCT-CI score may predict mortality for nonmalignant disease
MDedge Hematology and Oncology
High efficacy, no safety signals for herpes zoster vaccine post-HSCT
MDedge Hematology and Oncology
Cancer groups offer guidance on immune-related adverse events
MDedge Hematology and Oncology
Outpatient CAR T infusions feasible using liso-cel
MDedge Hematology and Oncology
Nonmyeloablative conditioning gets a radiation boost for severe hemoglobinopathies
MDedge Hematology and Oncology
KD025 shows promise for steroid-dependent cGVHD
MDedge Hematology and Oncology